Dupilumab, also known as Dupixent, has been found to significantly reduce dysphagia, one of the most prominent symptoms of patients suffering from eosinophilic esophagitis (EoE), according to a recent study presented by Evan S. Dellon, MD, MPH, FACG, Professor of Medicine and Adjunct Professor of Epidemiology at the Center for Esophageal Diseases and Swallowing at the University of North Carolina School of Medicine. Since its approval by the US Food and Drug Administration (FDA) for EoE, Dupilumab has demonstrated promising results in controlling symptoms of the disease. The ongoing phase 3 LIBERTY-EoE-TREET trial evaluating Dupilumab in patients with EoE has provided new data indicating a significant improvement in both mean days with any action taken for dysphagia relief and the number of days with more severe dysphagia at week 24 compared to placebo. With its proven efficacy, Dupilumab is emerging as a promising treatment option for patients with EoE.
